Pfizer Inc. $PFE Stake Boosted by Canandaigua National Bank & Trust Co.

Canandaigua National Bank & Trust Co. grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.5% during the 2nd quarter, HoldingsChannel reports. The fund owned 218,881 shares of the biopharmaceutical company’s stock after acquiring an additional 29,392 shares during the period. Canandaigua National Bank & Trust Co.’s holdings in Pfizer were worth $5,306,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Livelsberger Financial Advisory purchased a new position in shares of Pfizer during the 2nd quarter valued at $108,000. Goldstone Financial Group LLC grew its holdings in shares of Pfizer by 53.8% during the 2nd quarter. Goldstone Financial Group LLC now owns 25,241 shares of the biopharmaceutical company’s stock valued at $641,000 after acquiring an additional 8,832 shares in the last quarter. Boltwood Capital Management grew its holdings in shares of Pfizer by 2.1% during the 2nd quarter. Boltwood Capital Management now owns 57,854 shares of the biopharmaceutical company’s stock valued at $1,402,000 after acquiring an additional 1,205 shares in the last quarter. Quintet Private Bank Europe S.A. grew its holdings in shares of Pfizer by 30.2% during the 2nd quarter. Quintet Private Bank Europe S.A. now owns 468,523 shares of the biopharmaceutical company’s stock valued at $11,357,000 after acquiring an additional 108,608 shares in the last quarter. Finally, Teamwork Financial Advisors LLC grew its holdings in shares of Pfizer by 28.8% during the 2nd quarter. Teamwork Financial Advisors LLC now owns 64,438 shares of the biopharmaceutical company’s stock valued at $1,562,000 after acquiring an additional 14,398 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on PFE shares. Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. HSBC decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a report on Monday, May 19th. Berenberg Bank decreased their price objective on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a report on Thursday, May 29th. Bank of America upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Jefferies Financial Group upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Stock Down 3.8%

PFE stock opened at $23.91 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a 50-day moving average of $24.79 and a two-hundred day moving average of $24.27. The stock has a market capitalization of $135.94 billion, a price-to-earnings ratio of 12.72, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the prior year, the company earned $0.60 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. Pfizer’s dividend payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.